KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Common Equity (2016 - 2025)

Emergent BioSolutions' Common Equity history spans 16 years, with the latest figure at $522.6 million for Q4 2025.

  • For Q4 2025, Common Equity rose 8.24% year-over-year to $522.6 million; the TTM value through Dec 2025 reached $522.6 million, up 8.24%, while the annual FY2025 figure was $522.6 million, 8.24% up from the prior year.
  • Common Equity reached $522.6 million in Q4 2025 per EBS's latest filing, down from $582.5 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $1.6 billion in Q4 2021 to a low of $386.3 million in Q2 2024.
  • Average Common Equity over 5 years is $992.0 million, with a median of $827.4 million recorded in 2023.
  • Peak YoY movement for Common Equity: surged 41.68% in 2021, then tumbled 59.66% in 2024.
  • A 5-year view of Common Equity shows it stood at $1.6 billion in 2021, then decreased by 13.89% to $1.4 billion in 2022, then tumbled by 53.21% to $649.3 million in 2023, then dropped by 25.64% to $482.8 million in 2024, then grew by 8.24% to $522.6 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Common Equity are $522.6 million (Q4 2025), $582.5 million (Q3 2025), and $536.2 million (Q2 2025).